spacer
home > epc > winter 2018 > ticking boxes
PUBLICATIONS
European Pharmaceutical Contractor

Ticking Boxes

With the advent of novel immuno-therapeutic approaches to cancer, the world has entered a new stage of medicine. Rather than targeting cancer cells directly with traditional tools like chemotherapy or radiation, immunotherapy seeks ways to use the bodyís own immune system to eradicate or inhibit the growth of cancers.

The field of immuno-oncology (IO) focuses on determining how to activate pre-existing immune cells to attack cancerous targets. Monoclonal antibody therapies have shown to be successful in many indications and continue to be an effective and viable approach to treating cancer. According to Beth Kiernan, pharmaceutical research analyst at Thomson Reuters, therapeutic cancer vaccines currently comprise 14% of IO clinical trials (1). Although many vaccine trials are in early stages, advancement has been made into later stages, showing potential for desirable outcomes using this strategy.

Perhaps the most groundbreaking and rapidly expanding modality of IO is the development of the utilisation of checkpoint inhibitors. Though the industry is just scratching the surface of its promise, checkpoint inhibitors have profound implications on the future of oncological therapies, revolutionising the research industry. Checkpoint inhibitor therapies are able to span across cancer types and stages, providing hope even in the most despairing of circumstances.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Elizabeth Koury is Vice President of Scientific Affairs at LabConnect. She is responsible for leading a team of scientists, sample management professionals, and contract managers strategically supporting clients within the pharma industry. Elizabeth earned a bachelorís in biology/allied health from Elizabethtown College, US, and a masterís in pharmaceutical chemistry from Lehigh University, US. She has more than 20 years of experience in conducting and overseeing scientific research in the areas of neuroscience, oncology, and immunology.

Jeff Mayhew is Chief Development Officer at LabConnect. As one of the founding partners in 2002, he has three decades of operations and business development experience within the healthcare industry. Before starting LabConnect, Jeff was founder and Director of Nexus Health Management International, where he was involved in the development of inpatient behavioural health services in Southeast Asia. Prior to that, he served as Vice President of Strategic Alliance Development for Charter Behavioural Health Systems, among other key leadership positions.
spacer
Elizabeth Koury
spacer
spacer
spacer
Jeff Mayhew
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Quanticate Partners with CluePoints to Offer Data Quality Oversight capabilities

Quanticate, a data-focused clinical research organisation (CRO), has announced that it has partnered with CluePoints as part of its new Data Quality Oversight service.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement